GlaxoSmithKline (GSK) is planning to voluntarily withdraw the indication of niraparib for treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have
been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous
recombination deficiency positive status.
For more information read the GSK letter.
Posted 9/7/2022